NewcelX Ltd. SEC filings NCEL
NewcelX Ltd. has 417 filings in SEC EDGAR's recent list, going back to Dec 18, 2019. Its latest annual report, Form 20-F, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 4, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| POS AM | Post-effective amendment no. 3 to form f-1 | Sep 18, 2026 | — |
| F-3 | Shelf registration (foreign issuer) | Aug 20, 2026 | — |
| F-3/A | Amendment no. 1 to form f-3 | Jun 10, 2026 | — |
| F-3 | Shelf registration (foreign issuer) | May 11, 2026 | — |
| POS AM | Post-effective amendment no. 2 to form f-1 | May 5, 2026 | — |
| POS AM | Registration statement | Nov 6, 2025 | — |
| POS AM | Post-effective amendment no. 1 to form f-1 | Oct 24, 2025 | — |
| POS AM | Registration statement | Oct 17, 2025 | — |
| F-1 | Registration statement (foreign issuer) | Sep 25, 2025 | — |
| 424B3 | Prospectus | Sep 10, 2025 | — |
| F-4/A | Registration statement | Sep 3, 2025 | — |
| F-4/A | Registration statement | Jul 29, 2025 | — |
| F-4/A | Amendment no. 5 to form f-4 | Jul 18, 2025 | — |
| F-4/A | Registration statement | Jun 23, 2025 | — |
| F-4/A | Registration statement | Jun 9, 2025 | — |
| F-4/A | Registration statement | Mar 31, 2025 | — |
| F-4/A | Registration statement | Mar 3, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Feb 10, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Feb 5, 2025 | — |
| F-4 | Registration statement | Dec 30, 2024 | — |
| F-3/A | Amendment no. 1 to form f-3 | Nov 18, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | Oct 23, 2024 | — |
| F-1 | Registration statement (foreign issuer) | Aug 27, 2024 | — |
| 424B5 | Prospectus supplement | Jul 1, 2024 | — |
| F-1 | Registration statement (foreign issuer) | May 30, 2024 | — |
| 424B5 | Prospectus supplement | Mar 22, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | Jan 13, 2023 | — |
| F-3 | Shelf registration (foreign issuer) | Dec 6, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Jun 10, 2022 | — |
| 424B5 | Prospectus supplement | Apr 14, 2022 | — |
| 424B3 | Prospectus | Apr 13, 2022 | — |
| 424B5 | Prospectus supplement | Mar 4, 2022 | — |
| F-3 | Shelf registration (foreign issuer) | Feb 3, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Dec 20, 2021 | — |
| F-1/A | Amendment no. 1 to form f-1 | Nov 1, 2021 | — |
| F-1 | Registration statement (foreign issuer) | Oct 22, 2021 | — |
| POS AM | Post-effective amendment no. 3 to form f-1 | Sep 30, 2021 | — |
| POS AM | Post-effective amendment no. 2 to form f-1 | May 27, 2021 | — |
| 424B4 | Prospectus | Feb 1, 2021 | — |
| F-1/A | Amendment no. 5 to form f-1 | Jan 20, 2021 | — |
| F-1/A | Amendment no. 4 to form f-1 | Nov 17, 2020 | — |
| F-1/A | Amendment no. 3 to form f-1 | Nov 13, 2020 | — |
| F-1/A | Amendment no.2 to registration statement | Oct 19, 2020 | — |
| F-1/A | Amendment no.1 to form f-1 | Aug 31, 2020 | — |
| F-1 | Registration statement (foreign issuer) | Feb 28, 2020 | — |
Showing 45 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NCEL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Zurich
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1783036
- Former names
- NLS Pharmaceutics Ltd. (until Oct 30, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.